Seon Young Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seon Young Kim has a total of 202 co-authors. Here are the top co-authors by number of shared publications:
Gye Cheol Kwon
Department of Laboratory Medicine, Chungnam National University College of Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea
6 shared publicationsJimyung Kim
Department of Laboratory Medicine, Chungnam National University College of Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea
6 shared publications- Sang Mee Hwang
Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
6 shared publications - Dong Soon Lee
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea
5 shared publications - Gye Cheol Kwon
Department of Laboratory Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea
5 shared publications - Hyun Kyung Kim
Department of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea
5 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by Wiley in Transfusion
- Vol. 66 (11) , 2323-2334
Pretransfusion testing interference profile of IMC ‐002: A novel anti‐ CD47 monoclonal antibody engineered for minimized red cell binding
Background: CD47‐targeted agents can interfere with pretransfusion testing due to CD47 expression on red blood cells (RBCs). IMC‐002 is a novel anti‐CD47 human IgG4 monoclonal antibody engineered to minimize RBC binding; however, its interference profile during pretransfusion testing remains poorly characterized. Study Design and Methods: Whole blood samples were incubated with IMC‐002 and tested by tube, gel card, and automated methods for ABO/RhD typing, direct antiglobulin test (DAT), and RBC phenotyping. Plasma spiked with IMC‐002 underwent antibody screening by tube and gel methods, adsorption studies, and carryover assessment. Flow cytometry compared IMC‐002 binding between RBCs and T cells. Results: IMC‐002 interfered with ABO/RhD typing, DAT, and antibody screening, but the extent varied by assay. Forward grouping interference was mitigated by saline washing. In contrast, reverse grouping interference was most prominent in gel cards but was resolved in tube testing via saline replacement. Antibody screening showed panreactive false‐positive results, which were stronger in gel cards and with papain‐treated RBCs. However, the magnitude of interference was lower than that reported for other CD47‐targeted agents. Flow cytometry confirmed minimal IMC‐002 binding to RBCs compared to dose‐dependent binding to CD3+ T cells. Conclusions: IMC‐002 exhibits a distinct pretransfusion interference profile compared with previously reported CD47‐targeted agents. Its interference appears partly mitigable by routine laboratory measures and is consistent with its engineered low RBC affinity, underscoring the need for agent‐specific evaluation of CD47‐targeted therapeutics in transfusion practice.
- 31 August 2026
- Published by Wiley in Transfusion
- Vol. 66 (11) , 2323-2334
Open AccessPretransfusion testing interference profile of IMC ‐002: A novel anti‐ CD47 monoclonal antibody engineered for minimized red cell binding
Background: CD47‐targeted agents can interfere with pretransfusion testing due to CD47 expression on red blood cells (RBCs). IMC‐002 is a novel anti‐CD47 human IgG4 monoclonal antibody engineered to minimize RBC binding; however, its interference profile during pretransfusion testing remains poorly characterized. Study Design and Methods: Whole blood samples were incubated with IMC‐002 and tested by tube, gel card, and automated methods for ABO/RhD typing, direct antiglobulin test (DAT), and RBC phenotyping. Plasma spiked with IMC‐002 underwent antibody screening by tube and gel methods, adsorption studies, and carryover assessment. Flow cytometry compared IMC‐002 binding between RBCs and T cells. Results: IMC‐002 interfered with ABO/RhD typing, DAT, and antibody screening, but the extent varied by assay. Forward grouping interference was mitigated by saline washing. In contrast, reverse grouping interference was most prominent in gel cards but was resolved in tube testing via saline replacement. Antibody screening showed panreactive false‐positive results, which were stronger in gel cards and with papain‐treated RBCs. However, the magnitude of interference was lower than that reported for other CD47‐targeted agents. Flow cytometry confirmed minimal IMC‐002 binding to RBCs compared to dose‐dependent binding to CD3+ T cells. Conclusions: IMC‐002 exhibits a distinct pretransfusion interference profile compared with previously reported CD47‐targeted agents. Its interference appears partly mitigable by routine laboratory measures and is consistent with its engineered low RBC affinity, underscoring the need for agent‐specific evaluation of CD47‐targeted therapeutics in transfusion practice.
- 8 August 2026
- Published by Wiley in Cytometry Part B: Clinical Cytometry
Subtype‐specific immunophenotypic and cytogenetic patterns complement flow‐cytometric detection of measurable residual disease in B‐lymphoblastic leukemia
Measurable residual disease (MRD) is a key prognostic marker in B‐lymphoblastic leukemia (B‐ALL). Because immunophenotypic and cytogenetic features vary by genetic subtype and treatment phase, the clinical value of an integrated MRD strategy using multiparametric flow cytometry (MFC), fluorescence in situ hybridization (FISH), and immunoglobulin clonality next‐generation sequencing (NGS) warrants evaluation. This retrospective single‐center study included 136 patients with B‐ALL and 491 bone marrow MRD assessments. MRD was evaluated by an 8‐color MFC panel adapted from the modified EuroFlow protocol, targeted FISH probes with an exploratory integrated interpretation for low‐level signals, and IGH/IGK NGS. Immunophenotypic marker expression and associations with genetic subtypes were analyzed in MFC MRD‐positive samples. MRD levels were significantly correlated across modalities: MFC–FISH ( ρ = 0.762), MFC–NGS ( ρ = 0.674), and FISH–NGS ( ρ = 0.341). Using NGS as the molecular comparator, MFC showed higher sensitivity than FISH (41.0% vs. 31.8%) with specificity of 100.0% vs. 96.9%. Discordant MFC/FISH cases showed subtype‐associated patterns, with MFC−/FISH+ findings more frequently observed in cases with numerical chromosomal abnormalities (e.g., hyperdiploidy) and immunophenotypic features resembling hematogones. Immunophenotypic marker expression varied by subtype, with near absence of CD10 in KMT2A ‐rearranged B‐ALL and increased CD81 expression in TCF3::PBX1 cases. MRD positivity by any method was associated with significantly worse relapse‐free survival. MFC, FISH, and NGS demonstrate complementary but variable performance in MRD detection across B‐ALL subtypes. Immunophenotypic and cytogenetic heterogeneity influence the sensitivity of individual modalities, supporting the use of an integrated, multimodal approach for MRD surveillance.
- 8 August 2026
- Published by Wiley in Cytometry Part B: Clinical Cytometry
Subtype‐specific immunophenotypic and cytogenetic patterns complement flow‐cytometric detection of measurable residual disease in B‐lymphoblastic leukemia
Measurable residual disease (MRD) is a key prognostic marker in B‐lymphoblastic leukemia (B‐ALL). Because immunophenotypic and cytogenetic features vary by genetic subtype and treatment phase, the clinical value of an integrated MRD strategy using multiparametric flow cytometry (MFC), fluorescence in situ hybridization (FISH), and immunoglobulin clonality next‐generation sequencing (NGS) warrants evaluation. This retrospective single‐center study included 136 patients with B‐ALL and 491 bone marrow MRD assessments. MRD was evaluated by an 8‐color MFC panel adapted from the modified EuroFlow protocol, targeted FISH probes with an exploratory integrated interpretation for low‐level signals, and IGH/IGK NGS. Immunophenotypic marker expression and associations with genetic subtypes were analyzed in MFC MRD‐positive samples. MRD levels were significantly correlated across modalities: MFC–FISH ( ρ = 0.762), MFC–NGS ( ρ = 0.674), and FISH–NGS ( ρ = 0.341). Using NGS as the molecular comparator, MFC showed higher sensitivity than FISH (41.0% vs. 31.8%) with specificity of 100.0% vs. 96.9%. Discordant MFC/FISH cases showed subtype‐associated patterns, with MFC−/FISH+ findings more frequently observed in cases with numerical chromosomal abnormalities (e.g., hyperdiploidy) and immunophenotypic features resembling hematogones. Immunophenotypic marker expression varied by subtype, with near absence of CD10 in KMT2A ‐rearranged B‐ALL and increased CD81 expression in TCF3::PBX1 cases. MRD positivity by any method was associated with significantly worse relapse‐free survival. MFC, FISH, and NGS demonstrate complementary but variable performance in MRD detection across B‐ALL subtypes. Immunophenotypic and cytogenetic heterogeneity influence the sensitivity of individual modalities, supporting the use of an integrated, multimodal approach for MRD surveillance.
- Open Access
- 2 April 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (3) , 239-240
Advances and Challenges in Fusion Gene Detection in Acute Leukemia
Seon Young Kim, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0135
- 2 April 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (3) , 239-240
Open AccessAdvances and Challenges in Fusion Gene Detection in Acute Leukemia
Seon Young Kim, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0135
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Real-World Outcomes of Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: Implications for Extended Prophylaxis Strategies
Kim SA, et al. J Korean Med Sci. 2026 Dec;41:e330. https://doi.org/10.3346/jkms.2026.41.e330
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Open AccessReal-World Outcomes of Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: Implications for Extended Prophylaxis Strategies
Kim SA, et al. J Korean Med Sci. 2026 Dec;41:e330. https://doi.org/10.3346/jkms.2026.41.e330
- 22 December 2025
- Published by Elsevier in Leukemia Research
- Vol. 160, 108156
Genomic profiles of myelodysplastic neoplasm with bone marrow eosinophilia or basophilia: Inflammatory drivers and DNA damage response
- 22 December 2025
- Published by Elsevier in Leukemia Research
- Vol. 160, 108156
Genomic profiles of myelodysplastic neoplasm with bone marrow eosinophilia or basophilia: Inflammatory drivers and DNA damage response
- 27 September 2025
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (1) , 63-70
Atypical Lymphocytosis Induced by T Cell‐Engaging Therapy in Patients With Hematological Malignancies
Introduction: Atypical lymphocytes (ALYs) are activated lymphocytes with distinct morphological characteristics, often observed in various infections, autoimmune diseases, drug reactions, and malignancies. Their appearance may resemble leukemic or lymphoma cells, making it essential to differentiate ALYs, particularly in patients with hematological malignancies. With the advent of T‐cell engagers (TCEs), a novel class of immuno‐oncology drugs, this study aimed to investigate their effect on peripheral blood profiles, including ALYs. Methods: We retrospectively analyzed complete blood count (CBC) data and peripheral blood morphology from 28 patients enrolled in clinical trials of various TCEs targeting multiple myeloma and B‐cell lymphomas. The drugs studied included cevostamab, linvoseltamab, glofitamab, teclistamab, talquetamab, elranatamab, and epcoritamab. Results: A transient increase in ALYs was observed in 11 of the 28 patients treated with TCEs. This was confirmed by changes in cell morphology and flow cytometric parameters obtained from the CBC analyzer. ALY elevation appeared to be influenced by drug type, administration route, and combination therapies. In addition, a sudden and transient decrease in both monocytes and lymphocytes was noted in peripheral blood following cevostamab treatment. Conclusion: The observed increase in ALYs likely reflects immune activation induced by TCEs. Understanding ALY dynamics during TCE treatment is crucial for clinicians and pathologists when interpreting patient test results. Furthermore, ALY testing may serve as a potential marker for predicting the effectiveness of TCE therapies.
- 27 September 2025
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (1) , 63-70
Atypical Lymphocytosis Induced by T Cell‐Engaging Therapy in Patients With Hematological Malignancies
Introduction: Atypical lymphocytes (ALYs) are activated lymphocytes with distinct morphological characteristics, often observed in various infections, autoimmune diseases, drug reactions, and malignancies. Their appearance may resemble leukemic or lymphoma cells, making it essential to differentiate ALYs, particularly in patients with hematological malignancies. With the advent of T‐cell engagers (TCEs), a novel class of immuno‐oncology drugs, this study aimed to investigate their effect on peripheral blood profiles, including ALYs. Methods: We retrospectively analyzed complete blood count (CBC) data and peripheral blood morphology from 28 patients enrolled in clinical trials of various TCEs targeting multiple myeloma and B‐cell lymphomas. The drugs studied included cevostamab, linvoseltamab, glofitamab, teclistamab, talquetamab, elranatamab, and epcoritamab. Results: A transient increase in ALYs was observed in 11 of the 28 patients treated with TCEs. This was confirmed by changes in cell morphology and flow cytometric parameters obtained from the CBC analyzer. ALY elevation appeared to be influenced by drug type, administration route, and combination therapies. In addition, a sudden and transient decrease in both monocytes and lymphocytes was noted in peripheral blood following cevostamab treatment. Conclusion: The observed increase in ALYs likely reflects immune activation induced by TCEs. Understanding ALY dynamics during TCE treatment is crucial for clinicians and pathologists when interpreting patient test results. Furthermore, ALY testing may serve as a potential marker for predicting the effectiveness of TCE therapies.
- Open Access
- 28 April 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 45 (5) , 539-544
Utility of ABO Genotyping by Integrating the ABO Gene into Diagnostic Gene Panels for Patients with Hematologic Malignancies
Yun Mi Park , M.D., Ph.D., Gye Cheol Kwon , M.D., Ph.D., and Seon Young Kim , M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0573
- 28 April 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 45 (5) , 539-544
Open AccessUtility of ABO Genotyping by Integrating the ABO Gene into Diagnostic Gene Panels for Patients with Hematologic Malignancies
Yun Mi Park , M.D., Ph.D., Gye Cheol Kwon , M.D., Ph.D., and Seon Young Kim , M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0573
- Open Access
- 1 January 2025
- Published by XMLink in International Journal of Heart Failure
- Vol. 7 (2) , 110-115
Poor Outcome of the p.Ser43Asn TTR Variant Causing Hereditary Transthyretin Amyloidosis in Korea
An SY, et al. Int J Heart Fail. 2025 Apr;7(2):110-115. https://doi.org/10.36628/ijhf.2024.0075
- 1 January 2025
- Published by XMLink in International Journal of Heart Failure
- Vol. 7 (2) , 110-115
Open AccessPoor Outcome of the p.Ser43Asn TTR Variant Causing Hereditary Transthyretin Amyloidosis in Korea
An SY, et al. Int J Heart Fail. 2025 Apr;7(2):110-115. https://doi.org/10.36628/ijhf.2024.0075
- 18 April 2024
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 71, 152317
Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies
- 18 April 2024
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 71, 152317
Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies